Amgen biopharmaceutical company
Amgen is an American biopharmaceutical company which was based in 1980. Amgen actively uses the methods of gene engineering and innovative pharmaceutical products in its manufacturing practice.
This is the largest and promising company in the field of the development of the medical products on the basis of protein molecule of human. There are products of the chemical synthesis – small molecule along with gene engineering protein molecule.
Amgen has an active research activity in the field of the drug development to treat oncologic diseases. In 2013, the drugs Neulasta (used for the prophylaxis of infections after chemotherapy) and Enbrel (an autoimmune drug used as a blocker of tumor necrosis) had the highest sales in the company.
Today, the product portfolio of the company contains Aranesp, Blincyto, Corlanor, Enbrel, Epogen, Imlygic, Kyprolis, Neulasta, Neupogen, Nexavar, Nplate, Prolia, Repatha, Sensipar, Vectibix, and Xgeva.
Amgen has developed and sold several its own drugs to other pharmaceutical companies. These drugs are Kepivance, StemGen, and Kineret. Now, other pharmaceutical companies have exclusive rights to these brand names but that is the scientists of Amgen who have taken part in its development.
According to 2014, Amgen has 12 position in the top of the pharmaceutical companies with the biggest sales results. In spite of the small assortment of the medical production, the company produces drugs which are needed by people and really work.
At the moment, more than 10 medical drugs of Amgen company which may improve the life quality of people with oncologic and rheumatic diseases are at the stage of the medical studies.